Merck (MRK) Asset Writedowns and Impairment (2010 - 2023)

Merck (MRK) has reported Asset Writedowns and Impairment for 14 consecutive years, with $779.0 million the latest figure, recorded in Q4 2023.

• In Q4 2023, Asset Writedowns and Impairment fell 7.15% year-over-year to $779.0 million; the TTM figure through Dec 2023 stood at $2.8 billion (up 38.41% YoY), while the FY2025 annual figure was $55.0 million, up 41.03% from the prior year.
• Asset Writedowns and Impairment eased to $779.0 million in Q4 2023 per MRK's latest filing, from $839.0 million in the prior quarter.
• Across five years, Asset Writedowns and Impairment topped out at $1.7 billion in Q4 2020 and bottomed at $15.0 million in Q3 2020.
• Historically, Asset Writedowns and Impairment has averaged $505.9 million across 5 years, with a median of $302.0 million in 2021.
• On a YoY basis, Asset Writedowns and Impairment climbed as much as 856.25% in 2020 and fell as far as 97.55% in 2020.
• Merck's Asset Writedowns and Impairment stood at $176.0 million in 2019, then soared by 856.25% to $1.7 billion in 2020, then sank by 82.06% to $302.0 million in 2021, then jumped by 177.81% to $839.0 million in 2022, then slipped by 7.15% to $779.0 million in 2023.
• Business Quant data shows MRK's Asset Writedowns and Impairment at $779.0 million in Q4 2023, $839.0 million in Q4 2022, and $887.0 million in Q3 2022.